Global Cushing’s syndrome and Acromegaly Treatment Market: Overview
Cushing’s syndrome is cause by increased
production of corticosteroid hormones often resulting in high blood
pressure and obesity. On the other hand, Acromegaly is a chronic
disorder cause due to excess production of growth hormones. The global
Cushing’s syndrome and Acromegaly treatment market is anticipated to
display promising growth during the forecast period owing to the
advancements in the healthcare industry.
Report Overview @ https://www.transparencymarketresearch.com/cushings-syndrome-and-acromegaly-treatment-market.html
Below are a few notable developments in the global Cushing’s syndrome and Acromegaly treatment market:
- Development of Pegvisomant Therapy has proved to be a major breakthrough in the global Cushing’s syndrome and Acromegaly treatment market. Pegvisomant is a growth hormone receptor antagonist that functions by preventing the endogenous growth hormone from binding to its receptor. It has proven to considerably reduce the concentration of insulin-level growth factor 1, responsible for the spread of the disease. Development of this therapy has helped the Cushing’s syndrome and Acromegaly treatment market to expand its global footprints.
- Cabergoline, an oral agent has proven to be useful for the treatment of Cushing’s disesase. It is a dopamine receptor antagonist popularly used for the treatment of prolactinomas. This effectively reduces the level of urinary free cortisol and shrinks the pituitary adenoma to a level where it cannot be detected in an MRI, thereby aiding an efficient treatment of the disease. This has presented numerous growth opportunities for the global Cushing’s syndrome and Acromegaly treatment market.
Prominent players in the global Cushing’s
syndrome and Acromegaly treatment market comprise Inc., Bristol-Myers
Squibb Company, Novartis AG, Pfizer Inc., Corcept Therapeutics, Ipsen
Biopharmaceuticals, and HRA Pharma.
Development of new drug therapies with
minimal or no side effects has highly contributed to the expansion of
global Cushing’s syndrome and Acromegaly treatment market. Moreover, an
increasing support from governments for the treatment Cushing’s syndrome
and Acromegaly is anticipated to boost the market’s growth. Governments
support the treatment of these diseases by spreading awareness and
through funding
Additionally, there has been an increase
in the disposable incomes in the emerging countries leading to a greater
adoption of new treatments, thereby expediting the growth of global
Cushing’s syndrome and Acromegaly treatment market. Along with this,
rising prevalence of Cushing’s syndrome and Acromegaly has also
facilitated the industry’s growth.
Furthermore, advancements in computed
tomography and magnetic resonance imaging has impacted the market
favourably, thus flourishing its growth. In addition, rising expenditure
on healthcare facilities coupled with a high demand for non-invasive
treatments has highly driven the Cushing’s syndrome and Acromegaly
treatment market’s expansion.
Global Cushing’s Syndrome and Acromegaly Treatment Market: Regional Outlook
Regionally, North America is perceived to
lead the global Cushing’s syndrome and Acromegaly treatment market.
This is owing to a high purchasing power an technological advancements.
Europe is also expected to grow exponentially during the forecast period
owing to an extensive medical industry. Germany is the major
contributor to the Cushing’s syndrome and Acromegaly treatment market’s
growth in this region on account of the presence of key market players.
No comments:
Post a Comment